Here is an interesting story about how low a BP

New Post Public Reply Private Reply Replies (0) Message Board
Enjay
807
Here is an interesting story about how low a BP (Bristol-Myers Squibb in this case) would stoop to make/save money. Innocent until proven guilty, but the story certainly has some compelling details. Also shows the difficulty of negotiating with BP. Excerpts and link below.



Unidentified witnesses accuse Bristol Myers of scuttling timely FDA move on liso-cel to avoid $6.4B payout

Back in June, disgruntled Celgene shareholders filed a lawsuit against Bristol Myers Squibb, accusing the pharma giant of purposely slow-rolling Breyanzi’s approval to avoid making a $6.4 billion contingent value rights (CVR) payout tied to its big Celgene acquisition.

Now, eight unidentified witnesses are coming forth to detail “a series of deliberate or reckless acts” they say BMS took to slam the brakes on what they say could have been an otherwise swift approval for Breyanzi.

“Despite its entitlement to expedited review, Bristol successfully delayed the FDA’s regulatory approval of Liso-cel for just enough time to avoid the $6.4 billion CVR payout to investors through a series of deliberate or reckless acts that it falsely passed off as unforeseeable mistakes or as events out of its control,” a new complaint states, filed on Tuesday.

Upon discussing a potential BMS takeover, Celgene proposed structuring the CVR agreement to provide separate payouts based on FDA approval of each of the company’s five late-stage assets. But BMS “flatly refused” that structure, according to the complaint, stating it was “unwilling to pay any amount under a CVR agreement unless all milestones were achieved” before the specified dates.

They put $6.4 billion into a CVR that required an FDA approval for Zeposia, Breyanzi and Abecma, each by an established date. Breyanzi — liso-cel — had a deadline of December 31, 2020.

They didn’t make the deadline on Breyanzi, and the CVR became worthless.

Celgene had repeatedly stated — even after announcing the merger — that Breyanzi was on track for a BLA submission in the second half of 2019, with an approval expected in mid-2020. Celgene submitted the first component of its BLA in September 2019, and the FDA found no issues with that portion, according to the complaint. However, BMS took three months to submit the next portion (CMC), and the FDA later stated that it found “significant additional omissions” in BMS’ BLA.

The complaint alleges that BMS left out “volumes of basic information,” including omissions that were “glaringly obvious, particularly for a drug company of Bristol’s sophistication and experience, and would have needed to be approved by Bristol senior executives.”

Regulators also found “a litany of basic and easily avoidable deficiencies at both of the facilities where Liso-cel was being manufactured,” the complaint argues. Addressing these manufacturing deficiencies required supplemental regulatory submissions from BMS, but those submissions were also deficient and required further supplementation, the plaintiffs allege.

At one point, the FDA concluded that new information provided by BMS was so substantial that it required a major amendment, which one witness (a former executive director at BMS) called a “major blunder.”

Breyanzi ended up securing approval just 36 days past the milestone date. The drug raked in $87 million last year, according to BMS’ Q4 results.

“This unprecedented string of deficiencies in the Liso-cel approval process pushed FDA approval 36 days beyond the Milestone date, just long enough to spare Bristol a $6.4 billion payout to CVR holders, while allowing it to reap the economic benefits of bringing the lucrative drug to market after a modest delay,” the complaint states.

https://endpts.com/unidentified-witnesses-acc...4b-payout/

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 153

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 219

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 197

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 118

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Analyst Upgrades: Johnson & Johnson a Key Focus Today

Updated Category News Views 167

Exciting Analyst Upgrades in the Stock Market The stock market is constantly evolving, and today's news shining a spotlight on several major companies is particularly noteworthy. Top Wall Street analysts have made significant changes to their outlooks for various stocks, resulting in several upgrades. Let’s take a closer look at these changes and what they might mean...

Continue Reading
Albany International Corp Facing Legal Scrutiny Over Misstatements

Updated Category News Views 317

Albany International Corp Under Investigation Investors of Albany International Corp. are currently facing significant legal concerns that have given rise to an investigation. This inquiry is primarily centered on potential allegations of misleading statements issued by the company, which may have ultimately led to unexpected financial repercussions. As a well-known...

Continue Reading
Toncoin Experiences Notable Decline of Over 4% Today

Updated Category News Views 131

Toncoin Price Analysis for Recent Days Recently, Toncoin experienced a notable decline, with its price dropping by 4.56% in just 24 hours, settling at $5.42. This downturn is quite different from its strong performance last week, during which Toncoin rose by an impressive 5.0%, increasing from $5.16 to the current price. Recent Price Movements and Volatility A closer look...

Continue Reading
AgriFORCE Unveils Innovative Strategy for Digital Infrastructure Growth

Updated Category News Views 209

Revolutionizing the Digital Landscape: AgriFORCE's Strategy AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI), a key player in the digital infrastructure sector, has recently announced an innovative tri-pillar strategy designed to meet the growing global thirst for computational power. As demands for technology continue to rise, this comprehensive framework focuses on Bitcoin...

Continue Reading
Rethinking Infrastructure Finance: Unlocking Trillions

Updated Category News Views 32

Cracking Open the Infrastructure Conundrum If you think America’s infrastructure is crumbling because of a lack of money, you’re only half right. The real hiccup lies in how we’ve rigged the system to access the cash pile. That’s what Anton Steshenko from the University of Maryland’s Smith School is shouting from the rooftops. According to him, it’s not a...

Continue Reading